The FDA has approved the Barostim Neo system (CVRx) for the improvement of symptoms in patients with advanced heart failure who are not suited for treatment with other heart failure devices, such as cardiac resynchronisation therapy. A press release reports that, previously, the FDA gave the device a Breakthrough Device designation because it treats [...]